Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Lancet Haematol. 2017 Jan 12;4(2):e67–e74. doi: 10.1016/S2352-3026(16)30194-6

Figure 2. Ruxolitinib induced mobilization of CLL cells from lymph nodes to the peripheral blood.

Figure 2

Ruxolitinib treatment increased and then decreased absolute lymphocyte counts (ALC) of CLL patients. Mean changes in peripheral blood ALC are depicted. Overall, ALC increased initially and then decreased. Previously treated participants showed a dampened response compared to previously untreated participants.